Alendronate with and without cholecalciferol for osteoporosis: Results of a 15-week randomized controlled trial

Robert R. Recker, Paul Lips, Dieter Felsenberg, Kurt Lippuner, Laurent Benhamou, Federico Hawkins, Pierre D. Delmas, Clifford Rosen, Ronald Emkey, Gretel Salzmann, Weili He, Arthur C. Santora

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective: Many osteoporosis patients have low 25-hydroxyvitamin D (250HD) and do not take recommended vitamin D amounts. A single tablet containing both cholecalciferol (vitamin D3) and alendronate would improve vitamin D status concurrently, with a drug shown to reduce fracture risk. This study assessed the efficacy, safety, and tolerability of a once-weekly tablet containing alendronate 70 mg and cholecalciferol 70 μg (2800IU) (ALN + D) versus alendronate 70 mg alone (ALN). Methods: This 15-week, randomized, double-blind, multi-center, active-controlled study was conducted during a season when 250HD levels are declining, and patients were required to avoid sunlight and vitamin D supplements for the duration of the study. Men (n = 35) and postmenopausal women (n = 682) with osteoporosis and 250HD ≥ 9 ng/mL were randomized to ALN + D (n = 360) or ALN (n = 357). Main outcome measures: Serum 250HD, parathyroid hormone, bone-specific alkaline phosphatase (BSAP), and urinary N-tetopeptide collagen cross-links (NTX). Results: Serum 250HD declined from 22.2 to 18.6 ng/mL with ALN (adjusted mean change = -3.4; 95% confidence interval [CI]: -4.0 to -2.8), and increased from 22.1 to 23.1 ng/mL with ALN + D (adjusted mean change = 1.2; 95% CI: 0.6 to 1.8). At 15 weeks, adjusted mean 250HD was 26% higher (p <0.001, ALN + D versus ALN), the adjusted relative risk (RR) of 250HD <15 ng/mL (primary endpoint) was reduced by 64% (incidence 11% vs. 32%; RR = 0.36; 95% CI: 0.27 to 0.48 [p <0.001]), and the RR of 250HD <9 ng/mL (a secondary endpoint) was reduced by 91% (1% vs. 13%; RR = 0.09; 95% CI: 0.03 to 0.23 [p <0.001]). Antiresorptive efficacy was unaltered, as measured by reduction in bone turnover (BSAP and NTX). Conclusion: In osteoporosis patients who avoided sunlight and vitamin D supplements, this once-weekly tablet containing alendronate and cholecalciferol provided equivalent antiresorptive efficacy, reduced the risk of low serum 250HD, improved vitamin D status over 15 weeks, and was not associated with hypercalcemia, hypercalciuria or other adverse findings, versus alendronate alone.

Original languageEnglish
Pages (from-to)1745-1755
Number of pages11
JournalCurrent Medical Research and Opinion
Volume22
Issue number9
DOIs
StatePublished - Sep 2006

Fingerprint

Alendronate
Cholecalciferol
Osteoporosis
Vitamin D
Randomized Controlled Trials
Confidence Intervals
Tablets
Sunlight
Alkaline Phosphatase
Serum
Hypercalciuria
Bone and Bones
Bone Remodeling
Hypercalcemia
Parathyroid Hormone
Collagen
Outcome Assessment (Health Care)
Safety
Incidence
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Alendronate with and without cholecalciferol for osteoporosis : Results of a 15-week randomized controlled trial. / Recker, Robert R.; Lips, Paul; Felsenberg, Dieter; Lippuner, Kurt; Benhamou, Laurent; Hawkins, Federico; Delmas, Pierre D.; Rosen, Clifford; Emkey, Ronald; Salzmann, Gretel; He, Weili; Santora, Arthur C.

In: Current Medical Research and Opinion, Vol. 22, No. 9, 09.2006, p. 1745-1755.

Research output: Contribution to journalArticle

Recker, RR, Lips, P, Felsenberg, D, Lippuner, K, Benhamou, L, Hawkins, F, Delmas, PD, Rosen, C, Emkey, R, Salzmann, G, He, W & Santora, AC 2006, 'Alendronate with and without cholecalciferol for osteoporosis: Results of a 15-week randomized controlled trial', Current Medical Research and Opinion, vol. 22, no. 9, pp. 1745-1755. https://doi.org/10.1185/030079906X120913
Recker, Robert R. ; Lips, Paul ; Felsenberg, Dieter ; Lippuner, Kurt ; Benhamou, Laurent ; Hawkins, Federico ; Delmas, Pierre D. ; Rosen, Clifford ; Emkey, Ronald ; Salzmann, Gretel ; He, Weili ; Santora, Arthur C. / Alendronate with and without cholecalciferol for osteoporosis : Results of a 15-week randomized controlled trial. In: Current Medical Research and Opinion. 2006 ; Vol. 22, No. 9. pp. 1745-1755.
@article{4f8c97ee35d841f0a3e73051ce751a89,
title = "Alendronate with and without cholecalciferol for osteoporosis: Results of a 15-week randomized controlled trial",
abstract = "Objective: Many osteoporosis patients have low 25-hydroxyvitamin D (250HD) and do not take recommended vitamin D amounts. A single tablet containing both cholecalciferol (vitamin D3) and alendronate would improve vitamin D status concurrently, with a drug shown to reduce fracture risk. This study assessed the efficacy, safety, and tolerability of a once-weekly tablet containing alendronate 70 mg and cholecalciferol 70 μg (2800IU) (ALN + D) versus alendronate 70 mg alone (ALN). Methods: This 15-week, randomized, double-blind, multi-center, active-controlled study was conducted during a season when 250HD levels are declining, and patients were required to avoid sunlight and vitamin D supplements for the duration of the study. Men (n = 35) and postmenopausal women (n = 682) with osteoporosis and 250HD ≥ 9 ng/mL were randomized to ALN + D (n = 360) or ALN (n = 357). Main outcome measures: Serum 250HD, parathyroid hormone, bone-specific alkaline phosphatase (BSAP), and urinary N-tetopeptide collagen cross-links (NTX). Results: Serum 250HD declined from 22.2 to 18.6 ng/mL with ALN (adjusted mean change = -3.4; 95{\%} confidence interval [CI]: -4.0 to -2.8), and increased from 22.1 to 23.1 ng/mL with ALN + D (adjusted mean change = 1.2; 95{\%} CI: 0.6 to 1.8). At 15 weeks, adjusted mean 250HD was 26{\%} higher (p <0.001, ALN + D versus ALN), the adjusted relative risk (RR) of 250HD <15 ng/mL (primary endpoint) was reduced by 64{\%} (incidence 11{\%} vs. 32{\%}; RR = 0.36; 95{\%} CI: 0.27 to 0.48 [p <0.001]), and the RR of 250HD <9 ng/mL (a secondary endpoint) was reduced by 91{\%} (1{\%} vs. 13{\%}; RR = 0.09; 95{\%} CI: 0.03 to 0.23 [p <0.001]). Antiresorptive efficacy was unaltered, as measured by reduction in bone turnover (BSAP and NTX). Conclusion: In osteoporosis patients who avoided sunlight and vitamin D supplements, this once-weekly tablet containing alendronate and cholecalciferol provided equivalent antiresorptive efficacy, reduced the risk of low serum 250HD, improved vitamin D status over 15 weeks, and was not associated with hypercalcemia, hypercalciuria or other adverse findings, versus alendronate alone.",
author = "Recker, {Robert R.} and Paul Lips and Dieter Felsenberg and Kurt Lippuner and Laurent Benhamou and Federico Hawkins and Delmas, {Pierre D.} and Clifford Rosen and Ronald Emkey and Gretel Salzmann and Weili He and Santora, {Arthur C.}",
year = "2006",
month = "9",
doi = "10.1185/030079906X120913",
language = "English",
volume = "22",
pages = "1745--1755",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Alendronate with and without cholecalciferol for osteoporosis

T2 - Results of a 15-week randomized controlled trial

AU - Recker, Robert R.

AU - Lips, Paul

AU - Felsenberg, Dieter

AU - Lippuner, Kurt

AU - Benhamou, Laurent

AU - Hawkins, Federico

AU - Delmas, Pierre D.

AU - Rosen, Clifford

AU - Emkey, Ronald

AU - Salzmann, Gretel

AU - He, Weili

AU - Santora, Arthur C.

PY - 2006/9

Y1 - 2006/9

N2 - Objective: Many osteoporosis patients have low 25-hydroxyvitamin D (250HD) and do not take recommended vitamin D amounts. A single tablet containing both cholecalciferol (vitamin D3) and alendronate would improve vitamin D status concurrently, with a drug shown to reduce fracture risk. This study assessed the efficacy, safety, and tolerability of a once-weekly tablet containing alendronate 70 mg and cholecalciferol 70 μg (2800IU) (ALN + D) versus alendronate 70 mg alone (ALN). Methods: This 15-week, randomized, double-blind, multi-center, active-controlled study was conducted during a season when 250HD levels are declining, and patients were required to avoid sunlight and vitamin D supplements for the duration of the study. Men (n = 35) and postmenopausal women (n = 682) with osteoporosis and 250HD ≥ 9 ng/mL were randomized to ALN + D (n = 360) or ALN (n = 357). Main outcome measures: Serum 250HD, parathyroid hormone, bone-specific alkaline phosphatase (BSAP), and urinary N-tetopeptide collagen cross-links (NTX). Results: Serum 250HD declined from 22.2 to 18.6 ng/mL with ALN (adjusted mean change = -3.4; 95% confidence interval [CI]: -4.0 to -2.8), and increased from 22.1 to 23.1 ng/mL with ALN + D (adjusted mean change = 1.2; 95% CI: 0.6 to 1.8). At 15 weeks, adjusted mean 250HD was 26% higher (p <0.001, ALN + D versus ALN), the adjusted relative risk (RR) of 250HD <15 ng/mL (primary endpoint) was reduced by 64% (incidence 11% vs. 32%; RR = 0.36; 95% CI: 0.27 to 0.48 [p <0.001]), and the RR of 250HD <9 ng/mL (a secondary endpoint) was reduced by 91% (1% vs. 13%; RR = 0.09; 95% CI: 0.03 to 0.23 [p <0.001]). Antiresorptive efficacy was unaltered, as measured by reduction in bone turnover (BSAP and NTX). Conclusion: In osteoporosis patients who avoided sunlight and vitamin D supplements, this once-weekly tablet containing alendronate and cholecalciferol provided equivalent antiresorptive efficacy, reduced the risk of low serum 250HD, improved vitamin D status over 15 weeks, and was not associated with hypercalcemia, hypercalciuria or other adverse findings, versus alendronate alone.

AB - Objective: Many osteoporosis patients have low 25-hydroxyvitamin D (250HD) and do not take recommended vitamin D amounts. A single tablet containing both cholecalciferol (vitamin D3) and alendronate would improve vitamin D status concurrently, with a drug shown to reduce fracture risk. This study assessed the efficacy, safety, and tolerability of a once-weekly tablet containing alendronate 70 mg and cholecalciferol 70 μg (2800IU) (ALN + D) versus alendronate 70 mg alone (ALN). Methods: This 15-week, randomized, double-blind, multi-center, active-controlled study was conducted during a season when 250HD levels are declining, and patients were required to avoid sunlight and vitamin D supplements for the duration of the study. Men (n = 35) and postmenopausal women (n = 682) with osteoporosis and 250HD ≥ 9 ng/mL were randomized to ALN + D (n = 360) or ALN (n = 357). Main outcome measures: Serum 250HD, parathyroid hormone, bone-specific alkaline phosphatase (BSAP), and urinary N-tetopeptide collagen cross-links (NTX). Results: Serum 250HD declined from 22.2 to 18.6 ng/mL with ALN (adjusted mean change = -3.4; 95% confidence interval [CI]: -4.0 to -2.8), and increased from 22.1 to 23.1 ng/mL with ALN + D (adjusted mean change = 1.2; 95% CI: 0.6 to 1.8). At 15 weeks, adjusted mean 250HD was 26% higher (p <0.001, ALN + D versus ALN), the adjusted relative risk (RR) of 250HD <15 ng/mL (primary endpoint) was reduced by 64% (incidence 11% vs. 32%; RR = 0.36; 95% CI: 0.27 to 0.48 [p <0.001]), and the RR of 250HD <9 ng/mL (a secondary endpoint) was reduced by 91% (1% vs. 13%; RR = 0.09; 95% CI: 0.03 to 0.23 [p <0.001]). Antiresorptive efficacy was unaltered, as measured by reduction in bone turnover (BSAP and NTX). Conclusion: In osteoporosis patients who avoided sunlight and vitamin D supplements, this once-weekly tablet containing alendronate and cholecalciferol provided equivalent antiresorptive efficacy, reduced the risk of low serum 250HD, improved vitamin D status over 15 weeks, and was not associated with hypercalcemia, hypercalciuria or other adverse findings, versus alendronate alone.

UR - http://www.scopus.com/inward/record.url?scp=33748995408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748995408&partnerID=8YFLogxK

U2 - 10.1185/030079906X120913

DO - 10.1185/030079906X120913

M3 - Article

C2 - 16968578

AN - SCOPUS:33748995408

VL - 22

SP - 1745

EP - 1755

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 9

ER -